• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Europe Hits Pause Button on Clinical Data As Brexit Stirs Staff Upheaval

Europe Hits Pause Button on Clinical Data As Brexit Stirs Staff Upheaval

August 6, 2018
William Myers

European regulators have stopped accepting and publishing clinical trials data, blaming the uncertainty of Brexit for staff cutbacks that the agency claims has disrupted its ability to function properly.

Officials at the European Medicines Agency (EMA) announced the decision last week but say it’s only temporary. The UK’s decision to leave the European Union has forced the EMA to move its headquarters from London to Amsterdam by March, which has caused “significant staff loss,” the regulator said in announcing the pause.

Last year, the EMA estimated it had around 700 employees. It predicted that the move from London to Amsterdam would cost about 200 jobs.

“The temporary cuts in activities are required because it has also become clear that the agency will lose more staff than initially anticipated,” the EMA said. “Staff who will not relocate to Amsterdam have already started to leave the agency and this trend is expected to accelerate.”

Dutch labor law also means that the EMA will have to shed some 135 short-term contractors in the move. Overall, the agency said it expects to lose about 30 percent of its staff by March.

The agency did not provide further specifics on the number or types of jobs lost or the timeline for its temporary measures. The cutbacks do not appear to affect clinical trials themselves but European regulators have stressed the importance of data transparency.

The EMA also wants to put some of its international efforts on hold, noting that for now it will focus on “urgent” drug safety guidelines and limit travel to “Brexit-related interactions.”

Even before last week’s announcement, European regulators had been sounding alarms about Brexit. Last month, the EMA released the results of a survey of drugmakers that found hundreds would have to rearrange at least part of their inspection or database operations because European law no long covers them in the UK.

A thin majority of voters supported a referendum pulling the UK out of the European Union in 2016. The following March, British Prime Minister Theresa May sent formal notice to the EU that her government was leaving, giving both sides a year to settle on terms of the divorce.

The EMA Brexit may disrupt drug approvals and safety inspections for two to three years after Brexit takes effect.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing